Hepatocyte growth factor activator inhibitor type‑1 in cancer: Advances and perspectives (Review)

Zheng,Qiaoli; Wu,Haijian; Cao,Jiang; Ye,Jingjia

doi:10.3892/mmr.2014.2628

Hepatocyte growth factor activator inhibitor type‑1 in cancer: Advances and perspectives (Review)

Authors:
- Qiaoli Zheng
- Haijian Wu
- Jiang Cao
- Jingjia Ye
View Affiliations

Affiliations: Clinical Research Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Published online on: October 13, 2014 https://doi.org/10.3892/mmr.2014.2628
Pages: 2779-2785

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer is one of the most common diseases, with high morbidity and mortality rates. Large‑scale efforts have been made to understand the pathogenesis of the disease, particularly in the advanced stages, in order to develop effective therapeutic approaches. Hepatocyte growth factor activator inhibitor type-1 (HAI-1), also known as serine protease inhibitor Kunitz type 1, inhibits the activity of several trypsin-like serine proteases. In particular, HAI-1 suppresses hepatocyte growth factor (HGF) activator and matriptase, resulting in subsequent inhibition of HGF/scatter factor and macrophage‑stimulating protein (MSP). HGF and MSP are involved in cancer development and progression, via the receptors Met receptor tyrosine kinase (RTK) and Ron RTK, respectively. Therefore, HAI-1-mediated downregulation of HGF and MSP signaling may suppress tumorigenesis and progression in certain types of cancers. Abnormal HAI-1 expression levels have been observed in various types of human cancer. The exact function of HAI-1 in cancer pathogenesis, however, has not been fully elucidated. In this review, the focus is on the potential impact of aberrant HAI-1 expression levels on tumorigenesis and progression, the underlying mechanisms, and areas that require further investigation to clarify the precise role of HAI-1 in cancer.

View Figures

View References

1	Parr C, Sanders AJ and Jiang WG: Hepatocyte growth factor activation inhibitors - therapeutic potential in cancer. Anticancer Agents Med Chem. 10:47–57. 2010. View Article : Google Scholar : PubMed/NCBI
2	Shimomura T, Denda K, Kitamura A, et al: Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem. 272:6370–6376. 1997. View Article : Google Scholar : PubMed/NCBI
3	Lin CY, Anders J, Johnson M and Dickson RB: Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem. 274:18237–18242. 1999. View Article : Google Scholar : PubMed/NCBI
4	Kirchhofer D, Peek M, Lipari MT, et al: Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579:1945–1950. 2005. View Article : Google Scholar
5	Hashimoto T, Kato M, Shimomura T and Kitamura N: TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. FEBS J. 277:4888–4900. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kato M, Hashimoto T, Shimomura T, et al: Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease. J Biochem. 151:179–187. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yao HP, Zhou YQ, Zhang R and Wang MH: MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer. 13:466–481. 2013. View Article : Google Scholar : PubMed/NCBI
8	Eigenbrot C, Ganesan R and Kirchhofer D: Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1). FEBS J. 277:2215–2222. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bugge TH, Antalis TM and Wu Q: Type II transmembrane serine proteases. J Biol Chem. 284:23177–23181. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kataoka H, Miyata S, Uchinokura S and Itoh H: Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev. 22:223–236. 2003. View Article : Google Scholar : PubMed/NCBI
11	Shimomura T, Denda K, Kawaguchi T, et al: Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. J Biochem. 126:821–828. 1999. View Article : Google Scholar
12	Kojima K, Tsuzuki S, Fushiki T and Inouye K: Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase. J Biol Chem. 283:2478–2487. 2008. View Article : Google Scholar : PubMed/NCBI
13	Denda K, Shimomura T, Kawaguchi T, Miyazawa K and Kitamura N: Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem. 277:14053–14059. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kirchhofer D, Peek M, Li W, et al: Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem. 278:36341–36349. 2003. View Article : Google Scholar : PubMed/NCBI
15	Miyata S, Fukushima T, Kohama K, et al: Roles of Kunitz domains in the anti-invasive effect of hepatocyte growth factor activator inhibitor type 1 in human glioblastoma cells. Hum Cell. 20:100–106. 2007. View Article : Google Scholar : PubMed/NCBI
16	Shia S, Stamos J, Kirchhofer D, et al: Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Bio. 346:1335–1349. 2005. View Article : Google Scholar : PubMed/NCBI
17	Fan B, Wu TD, Li W and Kirchhofer D: Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J Biol Chem. 280:34513–34520. 2005. View Article : Google Scholar : PubMed/NCBI
18	Parr C, Watkins G, Mansel RE and Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res. 10:202–211. 2004. View Article : Google Scholar : PubMed/NCBI
19	Kataoka H, Hamasuna R, Itoh H, Kitamura N and Koono M: Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res. 60:6148–6159. 2000.PubMed/NCBI
20	Yamauchi M, Kataoka H, Itoh H, et al: Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol. 171:890–896. 2004. View Article : Google Scholar : PubMed/NCBI
21	Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature. 412:822–826. 2001. View Article : Google Scholar : PubMed/NCBI
22	Wu QY and Parry G: Hepsin and prostate cancer. Front Biosci. 12:5052–5059. 2007. View Article : Google Scholar
23	Klezovitch O, Chevillet J, Mirosevich J, et al: Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 6:185–195. 2004. View Article : Google Scholar : PubMed/NCBI
24	Mok SC, Chao J, Skates S, et al: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 93:1458–1464. 2001. View Article : Google Scholar : PubMed/NCBI
25	Takahashi S, Suzuki S, Inaguma S, et al: Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers. Prostate. 54:187–193. 2003. View Article : Google Scholar : PubMed/NCBI
26	Parr C and Jiang WG: Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol. 19:857–863. 2001.PubMed/NCBI
27	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
28	Nakamura K, Abarzua F, Hongo A, et al: The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. Int J Oncol. 35:239–248. 2009.PubMed/NCBI
29	Nakamura K, Abarzua F, Hongo A, et al: Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma. Int J Oncol. 37:605–614. 2010. View Article : Google Scholar
30	Nakamura K, Hongo A, Kodama J and Hiramatsu Y: The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int J Cancer. 128:2613–2624. 2011. View Article : Google Scholar : PubMed/NCBI
31	Parr C and Jiang WG: Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer. 119:1176–1183. 2006. View Article : Google Scholar
32	Sanders AJ, Parr C, Mason MD and Jiang WG: Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med. 20:613–619. 2007.PubMed/NCBI
33	Baba T, Kawaguchi M, Fukushima T, et al: Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells’ invasiveness. J Pathol. 228:181–192. 2012.PubMed/NCBI
34	Cheng H, Fukushima T, Takahashi N, Tanaka H and Kataoka H: Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 69:1828–1835. 2009. View Article : Google Scholar
35	Fukushima T, Kawaguchi M, Yamasaki M, et al: Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci. 102:407–413. 2011. View Article : Google Scholar : PubMed/NCBI
36	Ye J, Kawaguchi M, Haruyama Y, et al: Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model. Cancer Sci. 105:44–51. 2014. View Article : Google Scholar
37	Nagata K, Hirono S, Ido A, et al: Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 289:205–211. 2001. View Article : Google Scholar : PubMed/NCBI
38	Zeng L, Cao J and Zhang X: Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol. 11:6202–6207. 2005.PubMed/NCBI
39	Oberst MD, Johnson MD, Dickson RB, et al: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res. 8:1101–1107. 2002.
40	Saleem M, Adhami VM, Zhong W, et al: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev. 15:217–227. 2006. View Article : Google Scholar
41	Funagayama M, Kondo K, Chijiiwa K and Kataoka H: Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes. World J Surg. 34:1563–1571. 2010. View Article : Google Scholar : PubMed/NCBI
42	Kataoka H, Suganuma T, Shimomura T, et al: Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem. 47:673–682. 1999. View Article : Google Scholar
43	Kang JY, Dolled-Filhart M, Ocal IT, et al: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63:1101–1105. 2003.
44	Nagaike K, Kohama K, Uchiyama S, et al: Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci. 95:728–735. 2004. View Article : Google Scholar : PubMed/NCBI
45	Warren M, Twohig M, Pier T, et al: Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol. 17:23–30. 2009. View Article : Google Scholar : PubMed/NCBI
46	Yasuda K, Komiya A, Watanabe A, et al: Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer. Anticancer Res. 33:575–581. 2013.PubMed/NCBI
47	Nagakawa O, Yamagishi T, Akashi T, Nagaike K and Fuse H: Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate. 66:447–452. 2006. View Article : Google Scholar : PubMed/NCBI
48	Hudson BD, Kulp KS and Loots GG: Prostate cancer invasion and metastasis: insights from mining genomic data. Brief Funct Genomics. 12:397–410. 2013. View Article : Google Scholar : PubMed/NCBI
49	Vogel LK, Saebø M, Skjelbred CF, et al: The ratio of Matriptase/HAI-l mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer. 6:1762006. View Article : Google Scholar
50	Tsai WC, Sheu LF, Chao YC, et al: Decreased Matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients. Chin J Physiol. 50:225–231. 2007.PubMed/NCBI
51	Naldini L, Weidner KM, Vigna E, et al: Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10:2867–2878. 1991.PubMed/NCBI
52	Graveel C, Su Y, Koeman J, et al: Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA. 101:17198–17203. 2004. View Article : Google Scholar
53	Ponzo MG, Lesurf R, Petkiewicz S, et al: Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA. 106:12903–12908. 2009. View Article : Google Scholar : PubMed/NCBI
54	Rong S, Segal S, Anver M, Resau JH and Vande Woude GF: Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA. 91:4731–4735. 1994. View Article : Google Scholar : PubMed/NCBI
55	Meiners S, Brinkmann V, Naundorf H and Birchmeier W: Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene. 16:9–20. 1998. View Article : Google Scholar
56	Gallego MI, Bierie B and Hennighausen L: Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 22:8498–8508. 2003. View Article : Google Scholar
57	Jeffers M, Fiscella M, Webb CP, et al: The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA. 95:14417–14422. 1998. View Article : Google Scholar : PubMed/NCBI
58	Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, et al: In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia. 8:353–363. 2006. View Article : Google Scholar
59	Abounader R and Laterra J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 7:436–451. 2005. View Article : Google Scholar : PubMed/NCBI
60	Bussolino F, Di Renzo MF, Ziche M, et al: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 119:629–641. 1992. View Article : Google Scholar
61	Grant DS, Kleinman HK, Goldberg ID, et al: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA. 90:1937–1941. 1993. View Article : Google Scholar : PubMed/NCBI
62	Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
63	Sami A and Karsy M: Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol. 34:1991–2002. 2013. View Article : Google Scholar : PubMed/NCBI
64	Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI
65	Boettner B and Van Aelst L: Control of cell adhesion dynamics by Rap1 signaling. Curr Opin Cell Biol. 21:684–693. 2009. View Article : Google Scholar : PubMed/NCBI
66	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
67	Berx G, Raspé E, Christofori G, Thiery JP and Sleeman JP: Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597. 2007. View Article : Google Scholar : PubMed/NCBI
68	Herter S, Piper DE, Aaron W, et al: Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390:125–136. 2005.PubMed/NCBI
69	Lee SL, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem. 275:36720–36725. 2000. View Article : Google Scholar : PubMed/NCBI
70	Takeuchi T, Harris JL, Huang W, et al: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem. 275:26333–26342. 2000. View Article : Google Scholar
71	Liotta LA: Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 46:1–7. 1986.PubMed/NCBI
72	Hoshiko S, Kawaguchi M, Fukushima T, et al: Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer Res. 73:2659–2670. 2013. View Article : Google Scholar : PubMed/NCBI
73	Turner JR: Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 9:799–809. 2009. View Article : Google Scholar : PubMed/NCBI
74	Turksen K and Troy TC: Junctions gone bad: Claudins and loss of the barrier in cancer. Biochim Biophys Acta. 1816:73–79. 2011.PubMed/NCBI
75	Kataoka H, Shimomura T, Kawaguchi T, et al: Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem. 275:40453–40462. 2000. View Article : Google Scholar
76	Oberst MD, Williams CA, Dickson RB, Johnson MD and Lin CY: The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem. 278:26773–26779. 2003. View Article : Google Scholar